Market Overview:
The global alexipharmic drugs market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and growing demand for better healthcare facilities. Based on type, the tetraethylthiuram disulfide segment is expected to account for the largest share in the global alexipharmic drugs market in 2018. This can be attributed to its high efficacy in treating various types of chronic diseases such as cancer and tuberculosis. By application, hospital pharmacy is expected to account for the largest share in 2018 owing to increase use of these drugs for treatment purposes in hospitals across globe.
Product Definition:
Alexipharmic drugs are those which can counteract the effects of poisons. They are important for treating poisonings and overdoses.
Tetraethylthiuram Disulfide:
Tetraethylthiuram disulfide, commonly known as TEA, is an organic compound used in the production of a wide range of pharmaceutical products. It is a colorless and highly soluble in water form. Tetraethylthiuram disulfide has been reported to be slightly toxic by oral route; however, the toxicity is not severe enough to cause fatalities.
Glutathione:
Glutathione is an antioxidant used in the treatment of diseases caused by oxidation such as cancer, arthritis, and Alzheimer's disease. It is also used to treat hepatitis C and some skin problems like eczema & psoriasis. Alexipharmic drugs are medicines that block the action of glutathione in the liver cells; they prevent damage from being done to cells by free radicals (by-products of normal chemical reactions).
Application Insights:
The global alexipharmic drugs market by application is segmented into hospital pharmacy, drug store and online retail. In 2017, the hospital pharmacy segment dominated the market with a revenue of USD 446.0 million owing to an increasing number of hospitals and rising prevalence of chronic diseases that require long-term treatment. Moreover, growing awareness about pharmaceutical benefits under COVID-19 in U.S., Canada and some European countries will drive the demand for alexipharmic drugs in this region over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of key players, favorable reimbursement scenario, and increasing healthcare expenditure are some factors contributing to the growth of this regional market. Asia Pacific is expected to be the fastest-growing region over the forecast period owing to rising disposable income levels and improving healthcare infrastructure in emerging countries such as China and India. Moreover, an increase in awareness regarding drug safety & efficacy coupled with growing health concerns is also anticipated to drive demand for Alexipharmic drugs over this period.
The European region accounted for a significant share due its high concentration of pharmaceutical companies involved in R&D activities pertainingto medicines for sale via online retail pharmacies or hospital pharmacies (i.e., OTC). These companies include GlaxoSmithKline plc.
Growth Factors:
- Increasing incidence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. The rise in the number of people suffering from chronic diseases has led to a corresponding increase in demand for drugs that can effectively treat these conditions. Alexipharmic drugs are increasingly being used to treat a wide range of chronic diseases, including cancer, diabetes, and heart disease.
- Technological advancements: The pharmaceutical industry is constantly evolving with new technologies being developed to improve drug discovery and development processes. Alexipharmic drugs are benefiting from these technological advancements, with many now being developed through targeted drug delivery systems and nanotechnology-based approaches. This is helping to improve their efficacy and safety profiles while also reducing their overall development costs.
Scope Of The Report
Report Attributes
Report Details
Report Title
Alexipharmic Drugs Market Research Report
By Type
Tetraethylthiuram Disulfide, Glutathione, EDTA, Penicillamine, Methylene Blue, Diethylenetriaminepentaacetic Acid, 2-Aminoethanethiol, Sodium Nitrite, Dimercapto Propanol, Triethylenetetramine
By Application
Hospital Pharmacy, Drug Store, Online Retail
By Companies
Accord Healthcare (Intas), Actavis Elizabeth, Alpharma pharmaceuticals (Pfizer), Amneal pharms, Apotex, Ethypharm, Fresenius kabi, TEVA, Gavis Phaemaceuticals, Hikma farmaceutica, Accord Healthcare (Intas)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Alexipharmic Drugs Market Report Segments:
The global Alexipharmic Drugs market is segmented on the basis of:
Types
Tetraethylthiuram Disulfide, Glutathione, EDTA, Penicillamine, Methylene Blue, Diethylenetriaminepentaacetic Acid, 2-Aminoethanethiol, Sodium Nitrite, Dimercapto Propanol, Triethylenetetramine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Drug Store, Online Retail
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Accord Healthcare (Intas)
- Actavis Elizabeth
- Alpharma pharmaceuticals (Pfizer)
- Amneal pharms
- Apotex
- Ethypharm
- Fresenius kabi
- TEVA
- Gavis Phaemaceuticals
- Hikma farmaceutica
- Accord Healthcare (Intas)
Highlights of The Alexipharmic Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tetraethylthiuram Disulfide
- Glutathione
- EDTA
- Penicillamine
- Methylene Blue
- Diethylenetriaminepentaacetic Acid
- 2-Aminoethanethiol
- Sodium Nitrite
- Dimercapto Propanol
- Triethylenetetramine
- By Application:
- Hospital Pharmacy
- Drug Store
- Online Retail
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Alexipharmic Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Alexipharmic drugs are medications that work by blocking the action of histamine. Histamine is a chemical that is released during an allergic reaction, and can cause symptoms such as sneezing, itching, and difficulty breathing. Alexipharmic drugs are used to treat a variety of conditions, including hay fever, asthma, and seasonal allergies.
Some of the major players in the alexipharmic drugs market are Accord Healthcare (Intas), Actavis Elizabeth, Alpharma pharmaceuticals (Pfizer), Amneal pharms, Apotex, Ethypharm, Fresenius kabi, TEVA, Gavis Phaemaceuticals, Hikma farmaceutica, Accord Healthcare (Intas).
The alexipharmic drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Alexipharmic Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Alexipharmic Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Alexipharmic Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Alexipharmic Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Alexipharmic Drugs Market Size & Forecast, 2020-2028
4.5.1 Alexipharmic Drugs Market Size and Y-o-Y Growth
4.5.2 Alexipharmic Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Tetraethylthiuram Disulfide
5.2.2 Glutathione
5.2.3 EDTA
5.2.4 Penicillamine
5.2.5 Methylene Blue
5.2.6 Diethylenetriaminepentaacetic Acid
5.2.7 2-Aminoethanethiol
5.2.8 Sodium Nitrite
5.2.9 Dimercapto Propanol
5.2.10 Triethylenetetramine
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacy
6.2.2 Drug Store
6.2.3 Online Retail
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Alexipharmic Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Alexipharmic Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Tetraethylthiuram Disulfide
9.6.2 Glutathione
9.6.3 EDTA
9.6.4 Penicillamine
9.6.5 Methylene Blue
9.6.6 Diethylenetriaminepentaacetic Acid
9.6.7 2-Aminoethanethiol
9.6.8 Sodium Nitrite
9.6.9 Dimercapto Propanol
9.6.10 Triethylenetetramine
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacy
9.10.2 Drug Store
9.10.3 Online Retail
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Tetraethylthiuram Disulfide
10.6.2 Glutathione
10.6.3 EDTA
10.6.4 Penicillamine
10.6.5 Methylene Blue
10.6.6 Diethylenetriaminepentaacetic Acid
10.6.7 2-Aminoethanethiol
10.6.8 Sodium Nitrite
10.6.9 Dimercapto Propanol
10.6.10 Triethylenetetramine
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacy
10.10.2 Drug Store
10.10.3 Online Retail
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Tetraethylthiuram Disulfide
11.6.2 Glutathione
11.6.3 EDTA
11.6.4 Penicillamine
11.6.5 Methylene Blue
11.6.6 Diethylenetriaminepentaacetic Acid
11.6.7 2-Aminoethanethiol
11.6.8 Sodium Nitrite
11.6.9 Dimercapto Propanol
11.6.10 Triethylenetetramine
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacy
11.10.2 Drug Store
11.10.3 Online Retail
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Tetraethylthiuram Disulfide
12.6.2 Glutathione
12.6.3 EDTA
12.6.4 Penicillamine
12.6.5 Methylene Blue
12.6.6 Diethylenetriaminepentaacetic Acid
12.6.7 2-Aminoethanethiol
12.6.8 Sodium Nitrite
12.6.9 Dimercapto Propanol
12.6.10 Triethylenetetramine
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacy
12.10.2 Drug Store
12.10.3 Online Retail
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Tetraethylthiuram Disulfide
13.6.2 Glutathione
13.6.3 EDTA
13.6.4 Penicillamine
13.6.5 Methylene Blue
13.6.6 Diethylenetriaminepentaacetic Acid
13.6.7 2-Aminoethanethiol
13.6.8 Sodium Nitrite
13.6.9 Dimercapto Propanol
13.6.10 Triethylenetetramine
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacy
13.10.2 Drug Store
13.10.3 Online Retail
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Alexipharmic Drugs Market: Competitive Dashboard
14.2 Global Alexipharmic Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Accord Healthcare (Intas)
14.3.2 Actavis Elizabeth
14.3.3 Alpharma pharmaceuticals (Pfizer)
14.3.4 Amneal pharms
14.3.5 Apotex
14.3.6 Ethypharm
14.3.7 Fresenius kabi
14.3.8 TEVA
14.3.9 Gavis Phaemaceuticals
14.3.10 Hikma farmaceutica
14.3.11 Accord Healthcare (Intas)
